Bicycle Therapeutics PLC ADR BCYC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
-
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
-
Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
-
Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
Trading Information
- Previous Close Price
- $4.18
- Day Range
- $4.12–4.26
- 52-Week Range
- $3.92–9.18
- Bid/Ask
- $4.15 / $4.26
- Shares Outstanding
- 69.81M
- Market Cap
- $293.91M
- Volume/Avg
- 183,314 / 447,343
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.60
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 288
Valuation
|
Metric
|
BCYC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.53 |
Price/Sales | 4.60 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BCYC
|
|---|---|
Quick Ratio | 12.28 |
Current Ratio | 12.66 |
Interest Coverage | −1,193.81 |
Quick Ratio
BCYC
Profitability
|
Metric
|
BCYC
|
|---|---|
Return on Assets (Normalized) | −24.86% |
Return on Equity (Normalized) | −29.99% |
Return on Invested Capital (Normalized) | −32.35% |
Return on Assets
BCYC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&dbMt$& | LOCK|#$W?$ | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|V&P$y! | LOCK|$^sHS | $71B | |||
| argenx SE ADR
ARGX
| LOCK|^x!Trg | LOCK|%QY | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|PZ%>Y!> | LOCK|YD | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|M#x%qJ | LOCK|r^Q#B | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|YtQnL>W | LOCK|h&J?# | $26B | |||
| Moderna Inc
MRNA
| LOCK|h#SB!FP | LOCK|dl | $25B | |||
| Incyte Corp
INCY
| LOCK|z&L<nV^ | LOCK|$$J | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Y^zh#N | LOCK|%DL | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|?sW<pd | LOCK|x% | $16B |
United States